Canaccord Genuity Raises Helus Pharma Price Target to $58.00
Canaccord Genuity has increased its price target for Helus Pharma Inc. (HELP.CA) from $42.00 to $58.00 per share.
Stocks · News reference
Helus Pharma reports positive Phase 3 data as adjunctive depression drug HLP003 rapidly reduces symptoms through 12 weeks in adult patients.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Canaccord Genuity has increased its price target for Helus Pharma Inc. (HELP.CA) from $42.00 to $58.00 per share.
Helus Pharma reported positive topline results from its Phase 3 APPROACH study for HLP003 in major depressive disorder and announced key executive leadership changes alongside its fiscal second quarter 2027 financial results.
Helus Pharma reported positive topline results from its Phase 3 pivotal study, APPROACH, evaluating HLP003 as an adjunctive treatment for major depressive disorder.
Helus Pharma announced it will present topline results from its Phase 3 APPROACH study evaluating HLP003 for major depressive disorder on November 16, 2026. HLP003, a novel serotonergic agonist, has received FDA Breakthrough Therapy Designation. The company is also developing HLP004 for generalized anxiety disorder in Phase 2 trials.
Helus Pharma announced it will host a webcast on November 16, 2026, to reveal topline results from its Phase 3 APPROACH clinical trial evaluating HLP003 as an adjunctive treatment for major depressive disorder.
Helus Pharma announced that CEO Michael Halstead will participate in a fireside chat at the upcoming Guggenheim Healthcare Innovation Conference in Boston.